A Safety Extension Study of DR-OXY-301

Status Completed

Clinical Trial Summary

This is a safety extension study of DR-OXY-301 at pre-selected sites. Subjects who complete the DR-OXY-301 study are eligible to participate. The duration of this extension study will be up to approximately 42 weeks. Subjects will have physical and laboratory exams, including blood draws at each scheduled visit and colposcopic examination of the vagina and cervix. As in DR-OXY-301, subjects will be required to insert a vaginal ring; replacing it every 4 weeks. Subjects will also be required to keep a daily record of the number of times and the total amount of time the ring was outside the body each day and the reason for voluntary removal.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00782769
Study type	Interventional
Source	Teva Branded Pharmaceutical Products R&D, Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	September 2008
Completion date	July 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04578899` - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"	N/A
Active, not recruiting	`NCT03556891` - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence	N/A
Not yet recruiting	`NCT05977634` - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder	N/A
Completed	`NCT01955408` - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment	N/A
Recruiting	`NCT06201013` - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children	N/A
Recruiting	`NCT03727711` - TPTNS: Home vs Hospital Treatment for Overactive Bladder	N/A
Completed	`NCT00768521` - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)	Phase 1
Completed	`NCT03625843` - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing	N/A
Completed	`NCT02211846` - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder	Phase 1
Completed	`NCT02835846` - Investigation of the Effect of the Female Urinary Microbiome on Incontinence	Phase 4
Completed	`NCT02857816` - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB	N/A
Completed	`NCT02202031` - Controlling Urgency Through Relaxation Exercises	N/A
Withdrawn	`NCT02320201` - Foot Neuromodulation for Overactive Bladder in Children	N/A
Not yet recruiting	`NCT01409512` - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder	N/A
Not yet recruiting	`NCT01423838` - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder	Phase 4
Completed	`NCT01437670` - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin	N/A
Completed	`NCT01458197` - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.	Phase 2
Terminated	`NCT01758848` - Physical Therapy for Overactive Bladder	N/A
Withdrawn	`NCT01210859` - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents	N/A
Terminated	`NCT01003249` - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen	Phase 4